(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

Novavax Inc. jumped in early trading after US regulators fully approved its Covid vaccine, easing investors’ concerns after ...